ivWatch Honored as Finalist in the 2017 Medical Design Excellence Awards (MDEA)

Hampton, VA, May 1, 2017 — ivWatch, LLC, is pleased to announce that their Model 400, a peripheral IV monitoring device, is a finalist in the 19th Annual Medical Device Excellence Awards competition sponsored by MD&M East, the largest annual medical technology conference on the East Coast. Winners will be announced during the June conference in New York.

The Device
The ivWatch Model 400 is a device that continuously monitors a patient’s peripheral IV for the early detection of infiltrations – when medication or fluid leaks outside the vein into the surrounding tissue. Intravenous therapy is a routine part of treatment for nearly 80% of patients in the U.S., and more than 20% of these IVs may fail because of infiltration. Because every IV failure risks both a serious drug delivery error and tissue damage, earlier detection of those failures is the new and next step for minimizing this potential for patient harm.

ivWatch
The team at ivWatch are recognized leaders in the field of tissue optics, biomedical engineering, computational optical modeling and sensor design. The technological advance represented by this device addresses the challenge of delivering high performance sensitivity and accuracy of reporting, and aligns with the medical industry’s dedication to patient safety and quality of care.

Thanks to close collaboration with nurses and doctors, the Model 400 fits easily into existing workflows. Leading hospitals across the U.S. who have been using the Model 400 are realizing the benefits of this new technology, improving both the effectiveness of drug delivery and the safety of their patients.

MDEA
The MDEA competition recognizes significant achievements in medical product design and engineering that improve healthcare delivery and accessibility. The awards celebrate the accomplishments of the medical device manufacturers, their suppliers, and the people behind the scenes who are responsible for cutting-edge products that save lives, improve patient care, and transform medtech—one innovation at a time.

From Gary Warren, President & CEO of ivWatch
“It’s an honor to be named as one of the finalists,” says Gary Warren, ivWatch President & CEO. “Having our device recognized by the MDEA judges validates our commitment to helping reduce patient harm and improving patient safety outcomes.”

Suppliers who contributed to the development and production of the Model 400 are Insight Product Development, Phillips-Medisize Corp, Gulf Fiberoptics/Gulf Photonics, and Minnetronix.

Contact:
Leah Moore, Director, Marketing
ivWatch, LLC
855-489-2824 ext. 7031
leah.moore@ivwatch.com
http://www.ivWatch.com/

ivWatch, LLC Receives 2016 Virginia Governor’s Outstanding STEM Award for Science Innovation

ivWatch, LLC will be honored for their innovative device that provides early detection of IV infiltrations and can help reduce patient harm.

Williamsburg, VA – ivWatch, a medical devices company, is one of five recipients to receive a Virginia Outstanding STEM Award granted by Governor Terry McAuliffe’s office. ivWatch will be receiving the STEM Award for Science Innovation on February 25th at an event to be held at the Science Museum of Virginia. The STEM award honors professionals and business that have made significant contributions to science.

ivWatch is being honored for their ivWatch Model 400, a device that continuously monitors a patient’s peripheral IV for the early detection of infiltrations – when medication or fluid leaks outside the vein into the surrounding tissue. Peripheral IVs are one of the most common invasive medical procedures performed with over 300 million IV catheters sold in the U.S. annually. Yet, current medical reports peg the failure rate of IVs in excess of 20% due to infiltrations which can cause drug delivery errors and patient harm. To address this unmet need, the dedicated ivWatch team delivered an FDA-cleared device in 2015. The ivWatch Model 400 includes a noninvasive sensor that uses near-infrared light to detect changes in the optical properties of the tissue. The sensor is coupled to a highly intuitive pole-mounted patient monitor. The device will notify clinicians if conditions suggest an infiltration, allowing them to address the issue early to reduce patient harm. The ivWatch Model 400 represents a new option for medical professionals – a continuously monitored peripheral IV – that can reduce costs, risk, patient harm and medication dosing errors.

The ivWatch Model 400 is backed by 16 years of research and development in areas that include photon/tissue interaction modeling, signal processing algorithm development and optimization, user interface research and design and extensive clinical testing. Gary P. Warren, CEO of ivWatch and former NASA Engineer says “The depth of science behind the ivWatch product line is truly amazing. For a small company, our research and associated intellectual property in this area rivals anything I have seen coming from large companies, universities or government labs. We have an incredible team of talented people here and are honored by this award.”

ivWatch was also the winner of the Governor’s Virginia Velocity Competition in September 2015 for the best bio-science business plan.

 

ivWatch Wins First Place in Nationwide Innovation Challenge: Virginia Velocity Business Plan Competition

Williamsburg, Va – September 8, 2015 – This week the innovative work of ivWatch scientists, engineers and clinicians won top honors in a national competition. During a live competitive event held in Richmond, Virginia, ivWatch was awarded first place in the bioscience sector of the Virginia Velocity business plan competition.
The competition is part of Governor McAuliffe’s strategy for diversifying the state’s economy by encouraging the growth of innovative bioscience and energy companies. ivWatch competed against many worthy bioscience businesses from across the nation, all hoping to prove their value to a panel of judges with strong business and industry expertise.

Following two rounds of competition, ivWatch was identified by the panel as one of two finalists in the bioscience sector to compete for the top award.

“We are honored to be singled out for our commitment to innovation that advances patient safety – and proud to be a part of the new Virginia economy,” said Gary Warren, ivWatch CEO.

In addition to being recognized as the best emerging bioscience company in Virginia, ivWatch will receive a $225,000 cash prize to support the company’s growth plans.

# # #

Leah Moore, Director of Marketing, ivWatch, LLC
1.855.489.2824 ext. 7031
Leah.Moore@ivwatch.com

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest